Skip to main content
TipRanks
Go Ultimate75% OFF

Trinity Biotech (TRB0) Q3 2024 Earnings Report

0 Followers

DE:TRB0 Q3 2024 EPS Results

Actual EPS
-EUR 12.54
Consensus EPS
-EUR 14.77
Beat/Miss
Beat by +EUR 2.24
One Year Ago EPS
-EUR 23.94

DE:TRB0 Q3 2024 Revenue Results

Actual Revenue
EUR 13.86M
Expected Revenue
EUR 15.05M
Beat/Miss
Missed by -EUR 1.19M
YoY Revenue Growth
+12.21%

Earnings Announcement Details

Quarter
Q3 2024
Date
11/15/2024
Time
Before Open
Conference Call
Friday, November 15, 2024
DE:TRB0 Upcoming Earnings

Trinity Biotech's next earnings date is estimated for December 10, 2026, based on past reporting schedules.

Q3 2024 Earnings Call Audio

DE:TRB0 Q3 2024 Earnings Call
0:00 / 0:00

Q3 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2024 Earnings Call Summary

Q3 2024
Earnings Call Date:Nov 15, 2024|% Change Since:0.00%|
Earnings Call Sentiment|Neutral

The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.

Company Guidance

During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.

  • Revenue Growth in Q3 2024The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
  • TrinScreen HIV Sales ProjectionTrinity Biotech reiterated its guidance for TrinScreen sales of approximately $10 million for the full year 2024, reflecting strong market demand.
  • Reduction in Operating LossThe operating loss before restructuring and impairment charges decreased to $2.2 million from $4.5 million in Q3 2023, marking a 51% improvement.
  • NASDAQ Listing Compliance AchievedThe company successfully addressed NASDAQ listing deficiencies, removing an important overhang on its stock.
  • Cost Reduction InitiativesSG&A expenses decreased by $1.2 million to $6.5 million in Q3 2024, showcasing effective cost reduction measures.

DE:TRB0 Earnings History

DE:TRB0 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Dec 10, 20262026 (Q3)―--0.25――
Sep 03, 20262026 (Q2)―--0.3―
May 27, 20262026 (Q1)―--0.44―
Apr 08, 20262025 (Q4)―-6.25-13.1652.53% (+6.91)
Dec 11, 20252025 (Q3)―-0.25-0.4240.17% (+0.17)
Sep 02, 20252025 (Q2)-0.47--0.65―
May 21, 20252025 (Q1)―-――
May 15, 20252024 (Q4)―-13.16-10.23-28.65% (-2.93)
Nov 15, 20242024 (Q3)-14.77-12.54-23.9447.64% (+11.40)
Aug 14, 20242024 (Q2)-18.33-19.53-65.5570.21% (+46.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed